Gilead Sciences Inc
(LTS:0QYQ)
$
89.755
0.23 (0.26%)
Market Cap: 112.32 Bil
Enterprise Value: 132.90 Bil
PE Ratio: 109.56
PB Ratio: 6.12
GF Score: 75/100 
Gilead Sciences Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript
May 19, 2021 / 02:20PM GMT
Release Date Price:
$68.2
(-1.68%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Good morning, everyone. I'm Brian Abrahams, senior biotech analyst at RBC Capital Markets. Very pleased to have our next presenting company, Gilead, represented by their CFO, Andy Dickinson. Andy, thanks so much for joining us.
Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO
Thanks, Brian. I appreciate you having us. Happy to be here.
Questions & Answers
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst
Absolutely. Our pleasure. So maybe just kicking things off, coming off of a seasonally soft first quarter, with COVID exacerbating some of the usual dynamics. How are you -- what's the outlook for the rest of the year? How are you expecting things to progress? And what are you seeing that gives you confidence in a bounce-back?
Andrew D. Dickinson
Gilead Sciences, Inc. - Executive VP & CFO
Yes. That's a
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers